Mark Vachon is Director at bluebird bio, Inc. (BLUE). They have made 6 open-market trades across 1 company since 2017, most recently 2025-06-02.
CIK 0001614018
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BLUE | 1,245 | $6K |
Shares reported on the most recent Form 4, priced at the 2025-06-03 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BLUE | SELL | 2018-06-14 | 2018-06-18 | $190.00 | $190K | -13.5% | +0.1% | -23.5% |
| BLUE | SELL | 2018-06-04 | 2018-06-06 | $188.22 | $1.1M | -5.1% | -8.7% | -11.3% |
| BLUE | SELL | 2018-03-15 | 2018-03-19 | $214.31 | $1.4M | -12.2% | -10.2% | -9.2% |
| BLUE | SELL | 2017-12-11 | 2017-12-13 | $215.91 | $1.8M | -3.0% | -8.6% | +19.6% |
| BLUE | SELL | 2017-12-11 | 2017-12-13 | $216.82 | $1.5M | -3.0% | -8.6% | +19.6% |
| BLUE | SELL | 2017-09-12 | 2017-09-14 | $126.70 | $921K | -4.1% | +8.5% | +40.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.